Upgrade to SI Premium - Free Trial

TD Cowen on Alkermes (ALKS): 'we view the update as important initial validation beyond sleep disorders'

September 21, 2026 10:04 AM
TD Cowen analyst Joseph Thome reiterated a Buy rating and $58.00 price target on Alkermes (NASDAQ: ALKS).The analyst comments "Alkermes ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments